吉林哪个中医院看男科好(吉林急性细菌性前列腺炎治疗) (今日更新中)

WELLINGTON, Aug. 8 (Xinhua) -- A New Zealand study has found that people who work at least 50 hours a week can be up to three times more at risk of alcohol problems than people who work fewer hours.The study, conducted by the University of Otago, used data that followed more than 1,000 people born in Christchurch in 1977 through to age 30.Study leader Dr Sheree Gibb said it aimed to examine whether working hours were related to alcohol problems in early adulthood.Data from more than 1,000 participants at ages 25 and 30 showed a significant association between longer working hours and alcohol- related problems.Longer working hours were associated with higher levels of alcohol problems including frequent alcohol use and alcohol abuse or dependence.People who worked 50 hours or more on average a week were 1.8 to 3.3 times more likely to have alcohol-related problems than those who were not working, and about 1.2 to 1.5 times more likely to have alcohol-related problems than those who worked 30 to 49 hours a week.The higher risk of alcohol abuse for those who worked longer hours was evident in both men and women, according to the study.Gibb said the finding could suggest a need for consideration of policies and programs targeting individuals who worked long hours, with the aim of reducing rates of alcohol-related problems.The article had been accepted for publication by the UK-based journal Addiction.

HELSINKI, July 4 (Xinhua) -- A new Finnish research shows that sleeplessness may be hereditary, and insomniacs are more likely to die earlier than people with healthy sleep patterns.The research is the first to link insomnia with mortality risk, Finnish media reported on Monday.The research is conducted by the Institute of Occupational Health in collaboration with the University of Helsinki and the Finnish National Institute for Health and WelfareIn a large-scale twin study, the Finnish researchers followed the health status of 12,500 adult twin pairs during the years from 1990 to 2009. Twenty percent of the participants were suffering from sleeplessness symptoms, including difficulty in initiating sleep, nocturnal awakening and non-restorative sleep.The study found out that compared with unidentical twins, identical twins were more likely to suffer from similar insomnia symptoms. This finding indicates that genetic factors play a role in the formation of insomnia.Moreover, the participants were divided into three groups, according to their sleep qualities. Out of the participants, 48 percent were good sleepers, 40 percent average sleepers and 12 percent poor sleepers. The search result shows that insomnia-related symptoms may increase mortality risk.In addition, compared with good sleepers, 7 percent of the women and 22 percent of the men who were average sleepers were more likely to die earlier; and poor sleepers were 1.5 times more likely to die earlier.According to the researchers, sleeplessness is a common health problem among working-age cohort. Chronic sleeplessness raises the risk of many illnesses and accidents, and thus weakens people's quality of life and ability to operate properly.The experts suggest that insomniacs should seek medical treatment in time, and chronic insomnia patients should be better treated with non-drug therapy.

BEIJING, Sept. 27 (Xinhuanet) -- People having a dog is way healthier than those don't, both physically and mentally, media reports said Tuesday.People owning dogs are more likely to take exercises than those having none, according to a recent poll of Mars Petcare, a pet food company.Two thirds of the walks dog owners take each week are attributed to their dogs, according to the poll, in which over 1,000 adults were surveyed.The survey also showed that 44 percent of dog owners over 65 years old make exercises because of their dogs.Dogs are a great motivator for doing exercises, said Dr. Sandra McCune, an animal behaviorist and also co-author of the book, "The Health Benefits of Dog Walking for People and Pets".

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

BEIJING, June 13 (Xinhua) -- The Chinese government on Monday launched a week-long campaign throughout the country which aims to make the public think more about food safety.Vice Premier Li Keqiang relayed to the campaign's organizer that it is essential to publicize knowledge and regulations on food safety among the public.Li, member of the Politburo Standing Committee of the Communist Party of China (CPC) Central Committee, said that special operations and severe punishment should be adopted to decrease the likelihood of food safety scandals.As part of the campaign, a food safety inspection team under the National People's Congress (NPC) Standing Committee held a conclusive meeting in Beijing to review its two-month supervisory tour to Jiangsu, Hubei, Sichuan and other four provinces and regions in April and May.A statement released by the inspection team on Monday said it will issue a report on food safety problems to the NPC Standing Committee.China's food safety has become a major public concern since a nationwide tainted milk powder scandal was exposed in August 2008.China's top legislature passed the Food Safety Law in 2009 which was soon followed by a nationwide food safety inspection.In the latest food safety scandal, drinks and food sold on the mainland but produced in Taiwan have been found to contain the toxic plasticizer DEHP.China's Ministries of Public Security, Agriculture, Health, as well as the General Administration for Quality Supervision, State Food and Drug Administration are also involved in the campaign.

来源：资阳报